Clinical and translational advances in ovarian cancer therapy

被引：184

作者：

Konstantinopoulos, Panagiotis A. ^{[1
]}

Matulonis, Ursula A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

NATURE CANCER | 2023年 / 4卷 / 9期

关键词：

PHASE-III TRIAL; T VIGIL IMMUNOTHERAPY; PEGYLATED LIPOSOMAL DOXORUBICIN; RUCAPARIB MAINTENANCE TREATMENT; RECURRENT EPITHELIAL OVARIAN; CARBOPLATIN PLUS PACLITAXEL; PLATINUM-RESISTANT; PARP INHIBITOR; OPEN-LABEL; HOMOLOGOUS-RECOMBINATION;

D O I：

10.1038/s43018-023-00617-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and is initially very responsive to platinum-based chemotherapy. However, the majority of patients relapse following initial surgery and chemotherapy, highlighting the urgent need to develop new therapeutic strategies. In this Review, we outline the main therapeutic principles behind the management of newly diagnosed and recurrent epithelial ovarian cancer and discuss the current landscape of targeted and immune-based approaches. In this Review, Konstantinopoulos and Matulonis discuss recent clinical advances in the treatment of ovarian cancer and reflect on persisting challenges.

引用

页码：1239 / 1257

页数：19

共 198 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3]

[Anonymous], 2020, BIOSPACE

[4]

Armstrong Deborah K, 2022, J Natl Compr Canc Netw, V20, P972, DOI [10.6004/jnccn.2022.0047, 10.6004/jnccn.2022.0047]

[5] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[6] CCNE1 Amplification as a Therapeutic Target [J].

Au-Yeung, George ;

Mileshkin, Linda ;

Bowtell, David D. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) :1770-+

[7] 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes [J].

Aziz, Diar ;

Etemadmoghadam, Dariush ;

Caldon, C. Elizabeth ;

Au-Yeung, George ;

Deng, Niantao ;

Hutchinson, Ryan ;

Bowtell, David ;

Waring, Paul .

GYNECOLOGIC ONCOLOGY, 2018, 151 (02) :327-336

[8]

Banerjee S., 2021, Phase I Study of the Combination of the Dual RAF/MEK Inhibitor VS-6766 and the FAK Inhibitor Defactinib: Results of Efficacy in Low Grade Serous Ovarian Cancer

[9] Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Banerjee, Susana ;

Moore, Kathleen N. ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol ;

Bradley, William H. ;

Holmes, Eileen ;

Lowe, Elizabeth S. ;

DiSilvestro, Paul .

LANCET ONCOLOGY, 2021, 22 (12) :1721-1731

[10] ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). [J].

Banerjee, Susana N. ;

Monk, Bradley J. ;

Van Nieuwenhuysen, Els ;

Moore, Kathleen N. ;

Oaknin, Ana ;

Fabbro, Michel ;

Colombo, Nicoletta ;

O'Malley, David M. ;

Coleman, Robert L. ;

Pachter, Jonathan A. ;

Koustenis, Andrew G. ;

Patrick, Gloria ;

Leonard, Lorna ;

Grisham, Rachel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 6 7 8 9 10 →